EGFR and cholangiocarcinoma: Few explanations have been postulated for this racial response to immunotherapy across varied malignancies including CCA: Firstly, it has been proposed that ethnic differences in somatic mutations (such as STK11, TP53, and EGFR) existing between Asians and non-Asian populations, referred to as “Asian signature”, affect the efficacy of ICIs [38].